Palvella gets expedited FDA review, eyes 2027 self-launch of QTORIN rapamycin
The US regulator will decide on the microcystic lymphatic malformations application by 28 February 2027, putting Palvella on course to commercialise on its own if the drug is cleared.
Palvella Therapeutics has moved a step closer to its first commercial product. The US Food and Drug Administration has accepted the company's new drug application for QTORIN rapamycin in microcystic lymphatic malformations and fast-tracked it with a Priority Review designation, which is meant to shorten the agency's review compared with a standard timeline.
The regulator has set 28 February 2027 as the date by which it aims to act under the Prescription Drug User Fee Act. Palvella said that, subject to approval, it is preparing to bring the product to the US market itself in the first half of 2027, rather than through a commercial partner. The company did not provide further detail on launch plans in the information available.
Palvella announced the news on 5 November 2026 alongside its third-quarter results. It reported cash of $236.7 million and a net loss of $24.6 million for the quarter. The company gave no guidance in the material reviewed on how those resources relate to launch costs, and no pricing or revenue expectations were disclosed.
An FDA action date is not an approval, and the outcome of the review remains open.
Why it matters
- The 28 February 2027 decision date gives investors, partners and competitors in rare disease a fixed regulatory milestone for QTORIN rapamycin.
- Palvella's plan to go to market on its own in the first half of 2027 means it would carry commercial build-out itself if approved; no launch details have been given.
- The company reported $236.7 million in cash and a $24.6 million third-quarter net loss as it approaches a potential first launch.
Company's press release (SEC filing): Palvella Therapeutics, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
Imricor starts US launch of NorthStar iMR system after paediatric FDA clearances
FDA grants NeOnc Type B meeting on accelerated approval path for intranasal NEO100
CHMP backs Cosentyx for adolescents aged 12+ with moderate-to-severe hidradenitis suppurativa
TuHURA wins FDA IND clearance for VISTA antibody TBS-2025 in relapsed AML
CHMP backs Roche's Gazyvaro as add-on therapy for autoantibody-positive lupus
